ArticleHemaSphere2026
Autologous stem cell transplantation in major T-cell lymphoma entities: An analysis by the EBMT Lymphoma Working Party.
Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chidamide‑augmented BEAM conditioning and maintenance in first-remission T‑cell lymphoma: a single‑arm phase 2 experience.Bone marrow transplantation · 2026Article
- Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party.Journal of hematology & oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autologous stem cell transplantation (auto-SCT) is an established treatment for peripheral T-cell lymphoma (PTCL) to consolidate first remission and for patients with relapsed/refractory (r/r) disease. We aimed to examine the outcomes of patients with PTCL NOS, AITL, and ALK-negative ALCL undergoing auto-SCT between 2010 and 2022 and reported to EBMT. Adult patients with major T-cell entities who had received auto-SCT either up-front or for r/r disease were included. 2082 patients underwent up-front and 1249 salvage auto-SCT. Three-year progression-free (PFS) and overall survival (OS) after up-front auto-SCT were 55.2% and 73.1%. For r/r patients, 3-year PFS and OS were 42.6% and 59.5%. In multivariate analysis, male patients, histology other than ALK-negative ALCL, non-CR, and higher age at auto-SCT showed significantly lower PFS and OS after both, up-front and salvage auto-SCT, mostly reflecting the higher relapse incidence for these patients. Major outcomes did not significantly change when the analyses were restricted to the patients with PET-based response at auto-SCT (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.